Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.
about
Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 VaccinationEpidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriageOntogeny of early life immunityVaccines against invasive Salmonella disease: current status and future directionsImportance of circulating antibodies in protection against meningococcal diseaseDesigning vaccines for the twenty-first century societyStructural basis for lack of toxicity of the diphtheria toxin mutant CRM197The role of vaccination in preventing pneumococcal disease in adultsAge-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgGPneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.Salmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens.Mapping the laminin receptor binding domains of Neisseria meningitidis PorA and Haemophilus influenzae OmpP2.Pneumococcal Vaccination Strategies. An Update and Perspective.Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis.Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.Vaccines against poverty.Modelling the influence of foot-and-mouth disease vaccine antigen stability and dose on the bovine immune response.Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.Development of Streptococcus pneumoniae Vaccines Using Live VectorsB1b cells recognize protective antigens after natural infection and vaccination.Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humansSerum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccinationHumoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccinesPneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance.Meningococcal glycoconjugate vaccines.Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis.Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.Meningococcal conjugate vaccines: optimizing global impact.Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles.Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Protein conjugate polysaccharide vaccines: challenges in development and global implementation.Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in MaliVaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis - Niamey, Niger, June 2015.Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.
P2860
Q26739685-89812C99-F0F5-4021-AE07-B6EB18E16499Q26770707-D44211C2-F201-4FF3-9CAA-8AB5E195FB73Q27000632-B5BE5217-E589-47F6-AF4F-7CFDA55D2A91Q27007088-B2C53916-7749-48DC-B8F4-3E885CB96CB3Q27023516-144BF2EC-9FF7-4D65-972E-5AADC188B494Q27025703-7A1D5F0F-B1ED-40BA-B43E-C9977B3CE1B8Q27678104-8DEE67B1-FC9D-447E-A50F-15E82267D767Q28396749-E830BEB5-9532-4CD5-866B-3FA09647E433Q28741100-B59B1E0F-0888-49DA-97C8-611EE973A991Q30235055-3458A905-E1F3-48D5-9CBD-50ED3F169637Q30400261-479F3B3B-A71D-4721-B31E-ABF5E9F4C170Q31104611-0FB05835-CE32-4721-889E-6DBDE906684DQ33772409-7F76C991-0439-4BAD-82E7-E9D432F8490BQ33965527-A4BF239E-17E2-4439-A9CE-433B4E220F1BQ33988997-F28CE247-45C2-4979-A5B2-AC65DE1B9A2DQ34033849-A8558F21-5F7C-4EF3-BF54-518F6DA59C16Q34119892-147C0A44-9483-4A8A-99A0-8013DE668C4EQ34170015-8D7E1E9A-78C1-44E7-B7BD-CF8D0946A55CQ34289818-EC3A1DFB-2664-4D25-98AA-BADEE7516DC5Q34300720-286D5979-8F7B-4598-955E-F12E84C67F2FQ34316015-83953DF0-9ED0-4BD5-92D2-6EC7A5AA5C96Q34433081-78C7933D-5BA0-402B-B8C9-9A6E35EF4CE1Q34562262-CAF1916D-C216-4680-9B12-FD223B159A1EQ34738958-7F3A5624-460A-4089-83FB-00737D1F7FBBQ34760675-3D054087-F898-43F8-B944-4EB66F1D1954Q34798448-1496ABA5-13FC-4754-B088-160A5D71D7F1Q35022547-66674DFC-44E2-4BBC-A870-318151EE4AC3Q35058011-07FCEB7F-0FE0-4780-A073-692C0B954C3EQ35136893-BDC4E8A1-F7D2-459B-85F7-54A1B7CE900CQ35194824-48666ECA-C47D-40F6-8F99-8E1C136A8128Q35272921-FEC0E70E-47D8-4D10-8876-FC8B48F5D42CQ35328649-2F8E59CC-01BE-449F-B68B-C5CE4F9A0E33Q35547767-BD26AEBF-FE1D-4377-952F-744161BB2149Q35548057-295F3377-8AE0-41C6-9AEF-D8BB5FC78DD0Q35697891-BDC962CC-81D1-4CA6-97C2-9D39E65872B5Q35805284-AC41C91B-9CBE-41BC-8848-F8123A6C0585Q35993024-FDD0016A-7A45-4483-A2B2-4C21F13372F3Q36005810-C9620616-34A2-4798-82C0-26CC36AC17EEQ36011900-390E74F2-4664-489F-8278-91BC06722A38Q36083360-F8A73261-EAC9-4A24-9EDD-D2837DB79D42
P2860
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Maintaining protection against ...... saccharide conjugate vaccines.
@en
Maintaining protection against ...... saccharide conjugate vaccines.
@nl
type
label
Maintaining protection against ...... saccharide conjugate vaccines.
@en
Maintaining protection against ...... saccharide conjugate vaccines.
@nl
prefLabel
Maintaining protection against ...... saccharide conjugate vaccines.
@en
Maintaining protection against ...... saccharide conjugate vaccines.
@nl
P2860
P356
P1476
Maintaining protection against ...... ysaccharide conjugate vaccines
@en
P2093
Andrew J Pollard
P2860
P304
P356
10.1038/NRI2494
P577
2009-03-01T00:00:00Z